9 Nov 2012 17:34
THIS PRESS RELEASE AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN, OR INTO, DIRECTLY OR INDIRECTLY, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), CANADA, JAPAN OR AUSTRALIA OR TO ANY OTHER JURISDICTION WHERE SUCH AN ANNOUNCEMENT WOULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.
This press release is, for UK regulatory purposes, an advertisement and not a prospectus and investors should not subscribe for or purchase any securities referred to in this press release except on the basis of information in the prospectus published by MD Medical Group Investments Plc. This press release does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of MD Medical Group Investments Plc, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of MD Medical Group Investments Plc.
MD MEDICAL GROUP
ANNOUNCEMENT OF EXERCISE OF OVER-ALLOTMENT OPTION
9 November 2012 - MD Medical Group Investments Plc ("MD Medical Group", LSE: MDMG), Russia's leading provider of private women's and children's healthcare, today announces that in connection with its initial public offering (the "Offering") the over-allotment option granted by MD Medical Holding Limited, the selling shareholder, has been exercised by the Joint Bookrunners in respect of 1,564,066 ordinary shares in the form of global depositary receipts ("GDRs"), representing 6.94% of the base offer size.
The offering of shares in the form of GDRs was priced on 12 October at US$12 per GDR with one GDR representing an interest in one ordinary share. The over-allotment shares were sold at the offer price.
The total Offering size, including the over-allotment option, is US$289,218,828 comprising 24,101,569 GDRs. Following the exercise of the over-allotment option, MD Medical Group's free float will be approximately 32.1%.
For further information, contact:
MD Medical Group
Andrey Braginskiy (Investors)
Tel: +7 985 211 7478
ir@mospmc.ru
Anastasia Anichenkova (Media)
Tel: +7 495 332 6670 / +7 916 661 6242
a.anichenkova@mospmc.ru
M:Communications
Tom Blackwell / Anna Yarmarkova - Moscow
Tel: +7 495 363 2846
mdmg@mcomgroup.com
Sarah Macleod / Mary-Jane Elliott - London
Tel: +44 20 7920 2300
mdmg@mcomgroup.com
IMPORTANT NOTICE
This press-release does not constitute or form part of, and should not be construed as, an offer of securities to the public in the United Kingdom, nor is it intended to be an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000 (as amended) of the United Kingdom ("FSMA"). Consequently, this press-release is only being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FP Order"), (iii) high net worth entities falling within Article 49(2)(a)-(d) of the FP Order and (iv) other persons to whom it may lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment activity to which this press-release relates will only be available to, and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
This press-release is not an offer to sell nor a solicitation to buy any securities nor a prospectus for the purposes of applicable measures implementing EU Directive 2003/71/EC as may be amended from time to time. A prospectus has been prepared and is available to the public in accordance with Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive"). Investors should not subscribe for or purchase any securities referred to in this press release except on the basis of the information contained in the prospectus to be published by the Company in due course relating to the securities.
This press-release do not constitute a public offer or advertisement of any securities in the Russian Federation, an offer, or an invitation to make offers, to purchase, sell, exchange or transfer any securities in the Russian Federation or to the benefit of any Russian person and do not constitute an "advertisement" or "offering" of the securities in the Russian Federation within the meaning of Russian securities laws and must not be passed on to third parties or otherwise be made publicly available in the Russian Federation. No prospectus will be registered with respect to these securities in the Russian Federation and the securities referred to herein are not intended for, "offering", "placement" or "circulation" in the Russian Federation unless otherwise permitted under Russian law.
The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
Some of the information in this press release may contain projections or other forward‐looking statements regarding future events. The Company wishes to caution you that these statements are only predictions and that actual events or results may differ materially. The Company does not intend to update these statements to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
Not for publication, distribution or release in the United States of America (including its territories and possessions), Canada, Japan or Australia.
In connection with the offering, Deutsche Bank AG, London Branch or any agent or other person acting on its behalf may over-allot GDRs up to a maximum of 3,380,624 additional GDRs or effect other stabilisation transactions with a view to supporting the market price of the GDRs at a level higher than that which might otherwise prevail in the open market. Such stabilisation activities may be effected on any securities market, over-the-counter market, stock exchange or otherwise and may be undertaken at any time during the period commencing on the date of the announcement of the offer price and ending no later than 30 calendar days thereafter. However, there will be no obligation on Deutsche Bank AG, London Branch or any of its agents to effect stabilising transactions, and there can be no assurance that stabilising transactions will be undertaken. Such stabilising, if commenced, may be discontinued at any time without prior notice. In no event will measures be taken to stabilise the market price of the GDRs above the offer price.
Save as required by law or regulation, Deutsche Bank AG, London Branch does not intend to disclose the extent of any over-allotments made and/or stabilisation transactions conducted in relation to the offering.